Announcements

Island Pharmaceuticals has expanded its CRADA with USAMRIID to conduct a dose optimisation study for Galidesivir against Marburg virus, utilizing USAMRIID's BSL-4 containment facilities. The study is expected to commence next quarter with topline results in H2 2026, providing critical efficacy and pharmacokinetic data to support progression toward a pivotal FDA Animal Rule trial.

WHO has confirmed xaranetide as the International Nonproprietary Name (INN) for Argenica's lead drug candidate ARG-007 with no objections during public consultation. The recommended INN status is expected to be published shortly, establishing a globally recognised generic name for the neuroprotective therapeutic in development for stroke and acute neurological conditions.

Noxopharm has commenced manufacturing of SOF-SKN for a planned clinical trial later in 2026, with the process expected to take several weeks including quality control checks. The company is investigating prospects for a pilot study in cutaneous lupus erythematosus (CLE), a chronic autoimmune inflammatory disease with a global market worth over US$3.3 billion.

Pro Medicus Limited (PME) has been removed from the S&P/ASX 50 Index effective June 22, 2026, following the June quarterly rebalance by S&P Dow Jones Indices. ALS Limited (ALQ) will be added to the index in PME's place. This represents a change in PME's index constituents status.

Mayne Pharma received $14.4 million from Cosette Pharmaceuticals in payment of legal costs, interest, and costs associated with its application, following a Supreme Court of New South Wales order dated 29 May 2026. This payment represents recovery of costs from Mayne Pharma's successful legal proceedings against Cosette regarding the termination of a Scheme Implementation Deed, with the Court delivering judgment in favour of Mayne Pharma in October 2025. Cosette has appealed the October 2025 judgment, with the appeal hearing completed on 2-3 June 2026 and decision reserved.